Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

This episode focused on the most pressing unmet needs in RSV prevention and the clinical impact of newly approved options. Tan highlighted a key issue from the initial rollout of nirsevimab: supply ...

The case: A healthy 12-month-old girl presented with one small skin lesion over the right heel (Figure 1) for one month. On examination, her right lateral heel showed a round white pearl like hard ...

As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator ...

The FDA has approved an expanded pediatric indication for the SONU Band (SoundHealth) for at-home treatment of moderate-to-severe nasal congestion because of allergic and non-allergic rhinitis in ...

A study recently published in JAMA Pediatrics found that US states with permissive firearm laws saw significantly more pediatric firearm deaths following the 2010 Supreme Court ruling in McDonald v ...

Invasive Staphylococcus aureus infections remain a major cause of illness and death in neonatal intensive care units (NICUs), particularly among very low birth weight (VLBW) infants, according to a ...

On June 9, 2025, the FDA approved Merck's monoclonal antibody clesrovimab (Enflonsia) to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season, according to a ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent ...

The label expansion allows for immediate treatment at diagnosis in patients aged ≥3 years without cirrhosis or with compensated cirrhosis. In a phase 3 trial, 96.2% of patients with acute HCV achieved ...

Among a study population of adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis (AD) and skin of color, dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) ...